High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy

Wang, Haoyuan; Jiang, Shanshan; Zhang, Yaojun; Pan, Ke; Xia, Jianchuan; Chen, Minshan

doi:10.1186/1477-7819-12-226

Cited by 10 publications

(12 citation statements)

References 26 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, thymosin beta 10 ( TMSB10 , z-score: 5.62, FDR: 0.00, Entrez ID: 9168) showed the largest difference in expression levels among statistically significant up-regulated DEGs. There is ample evidence suggesting that TMSB10 is one of the key regulators of malignancy and metastasis in various types of cancers and PM and DM are well-known for its association with malignancy [66,67]. Together, our results suggest that the acquired malignancy in PM and DM may be the result of the abnormal expression of TMSB10 .…”

Section: Discussionsupporting

confidence: 50%

Meta-Analysis of Polymyositis and Dermatomyositis Microarray Data Reveals Novel Genetic Biomarkers

Song

Kim

Hong

et al. 2019

Genes

View full text Add to dashboard Cite

Polymyositis (PM) and dermatomyositis (DM) are both classified as idiopathic inflammatory myopathies. They share a few common characteristics such as inflammation and muscle weakness. Previous studies have indicated that these diseases present aspects of an auto-immune disorder; however, their exact pathogenesis is still unclear. In this study, three gene expression datasets (PM: 7, DM: 50, Control: 13) available in public databases were used to conduct meta-analysis. We then conducted expression quantitative trait loci analysis to detect the variant sites that may contribute to the pathogenesis of PM and DM. Six-hundred differentially expressed genes were identified in the meta-analysis (false discovery rate (FDR) < 0.01), among which 317 genes were up-regulated and 283 were down-regulated in the disease group compared with those in the healthy control group. The up-regulated genes were significantly enriched in interferon-signaling pathways in protein secretion, and/or in unfolded-protein response. We detected 10 single nucleotide polymorphisms (SNPs) which could potentially play key roles in driving the PM and DM. Along with previously reported genes, we identified 4 novel genes and 10 SNP-variant regions which could be used as candidates for potential drug targets or biomarkers for PM and DM.

show abstract

Section: Discussionsupporting

confidence: 50%

Meta-Analysis of Polymyositis and Dermatomyositis Microarray Data Reveals Novel Genetic Biomarkers

Song

Kim

Hong

et al. 2019

Genes

View full text Add to dashboard Cite

show abstract

“…Thymosin β10 (Tβ10) is a natural small molecule polypeptide that is widely distributed in many tissues with proven biological activities as an actin-sequestering protein involved in cell motility [28]. Tβ10 is associated with cell proliferation, cell morphology, cell migration and endocytosis, as well as participating in cytoskeleton assembly and presence [29].…”

Section: Discussionmentioning

confidence: 99%

Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome

Sui¹,

Gan²,

Gong³

et al. 2018

transl med commun

View full text Add to dashboard Cite

Background: Down Syndrome (DS) has a very high morbidity, according to statistics, the incidence rate of DS is as high as 1:700 among the new born babies. At present, there are still no effective prevention or treatment methods for the disease. We used a Western Blot technique to validate differentially expressed proteins between DS foetal umbilical cord blood plasma and healthy foetal peripheral blood plasma from pregnant women to identify new prenatal diagnostic biomarkers for down syndrome (DS) and establish a new non-invasive prenatal diagnosis method.Methods: We collected maternal peripheral blood (8 with foetal DS and 8 from normal foetuses) from April 2013 to January 2014, and separated the plasma. We combined the clinical characteristics and clinical differentially expressed proteins between DS foetal umbilical cord blood plasma and healthy foetal umbilical cord blood plasma to identify specific protein marker candidates and prepared monoclonal antibodies, which were then used for Western Blot technique to analyse the candidate markers.Results: In the DS foetal maternal plasma, serum amyloid P-component, Apolipoprotein E, Nucleosome assembly protein 1-like 1, Complement factor B,ERO1-like protein alpha, 2-oxoglutarate dehydrogenase-like, and Thymosin beta 10 were up-regulated proteins compared to the healthy control group, and the DS group showed higher expression, which agreed with the results from the DS foetal umbilical cord blood plasma. Conclusion:The up-regulated amyloid P-component, Apolipoprotein E, Nucleosome assembly protein 1-like 1, Complement factor B, ERO1-like protein alpha, 2-oxoglutarate dehydrogenase-like, Thymosin beta 10 all are upregulation, all of them have potential to be prenatal diagnosis biomarkers for DS, and these biomarkers can further reveal the pathogenesis of DS.

show abstract

“…Tissue microarray analysis by Sulpice et al ( 29 ) demonstrated increased expression of COL4A1 in the stroma of ICC. Abnormal expression of TMSB10 may contribute to the malignant progression of HCC, and high expression of TMSB10 predicts poor prognosis in patients with HCC following hepatectomy ( 34 ). High TMSB10 expression is significantly associated with clinicopathological features, poor prognosis, and distant metastases in patients with breast cancer ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

Cholangiocarcinoma‑associated genes identified by integrative analysis of gene expression data

et al. 2018

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is characterized by delayed diagnosis and poor survival rate. Research efforts have focused on novel diagnostic technologies for this type of cancer. Transcriptomic microarray technology is a useful research strategy for investigating the molecular properties of CCA. The objective of the present study was to identify candidate biomarkers with high potential for clinical application in CCA using a meta-analysis-based approach. Gene expression profiles of CCA were downloaded from the Gene Expression Omnibus database for integrated analysis. All differentially expressed genes (DEGs) were analyzed by Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Protein-protein interaction (PPI) networks were further constructed, hub proteins were identified and functional modules were extracted. Following integrated analysis of the seven eligible datasets (428 cases and 46 controls), a set of 1,080 DEGs was identified, including 710 upregulated and 370 downregulated genes. Functional enrichment analysis demonstrated that ‘chromosome organization’ was a significantly enriched GO term in the biological process category. ‘DNA replication’, ‘influenza A’, and ‘lysosome’ were the top three significantly enriched KEGG pathways. Furthermore, PPI network analysis indicated that the significant hub proteins were histone deacetylase 1, cullin-associated NEDD8-dissociated protein 1, ubiquitin D, early growth response protein 1 and glycogen synthase kinase 3β. The majority of these proteins are involved in CCA. These results provided a set of targets that may help researchers to clarify further the underlying mechanisms of CCA tumorigenesis.

show abstract

High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy

Cited by 10 publications

References 26 publications

Meta-Analysis of Polymyositis and Dermatomyositis Microarray Data Reveals Novel Genetic Biomarkers

Meta-Analysis of Polymyositis and Dermatomyositis Microarray Data Reveals Novel Genetic Biomarkers

Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome

Cholangiocarcinoma‑associated genes identified by integrative analysis of gene expression data

Contact Info

Product

Resources

About